reported in Nature (2004) that thymosin beta-4 promoted cardiomyocyte survival and improved cardiac function following experimentally induced infarction in mice
doi: 10.3389/fimmu.2025.1711756 Received 23 September 2025 Accepted 31 October 2025 Published 19 November 2025 Volume 16 - 2025 Edited by Jean-louis Mege, Aix-Marseille Universit, France Reviewed by Nadja Freund, Ruhr University Bochum, Germany Namrata Anand, University of Chicago Medical Center, United States Updates Copyright 2025 Su, Li, Yang, Yang, Wang, Ren, Bao, Lao and Luan
If one of these medications is the cause of APD, it should no longer be taken to help manage symptoms
The researchers recruited 120 individuals with excess weight and obesity (74 women and 46 men) for the analysis
Animal studies demonstrated dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumours in rodents treated with GLP-1 receptor agonists
Wegovy and Ozempic Health Concerns Wegovy (semaglutide) is a higher dose version of the blockbuster drug Ozempic, which was initially approved for the treatment of people with Type 2 diabetes, and is part of a popular new class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1RAs)
